Description of the domestic marketing status of mirikizumab

The original drug Mirikizumab has not yet been officially launched in China, so domestic patients have limited access to it, and the price and medical insurance reimbursement are still unclear. If patients want to use militizumab, they usually need to apply through clinical trials or special import channels, which are subject to approval processes and imported drug management systems. However, the experience of drug marketing overseas provides important reference for domestic clinical practice.

In the U.S. and European markets, militizumab has been widely used for moderate to severe ulcerative colitis and Crohn's disease (CD) , showing significant efficacy, including improving symptoms, reducing recurrence rates, and promoting intestinal mucosal repair. The drug provides two delivery methods: subcutaneous injection or intravenous injection, especially the once-monthly subcutaneous injection maintenance regimen, which significantly improves patient compliance and convenience of life, and reduces the complexity of long-term treatment. Research shows that the IL-23p19 targeting mechanism is stable and reliable in long-term maintenance treatment, and the side effects are relatively mild. Common ones include injection site reactions, mild upper respiratory tract infection, and a small amount of gastrointestinal discomfort.

When domestic doctors evaluate this drug, they usually focus on its long-term safety, maintenance of efficacy, and the impact of individualized dose adjustment on patients' lives, especially refractory or relapsed patients. As the drug approval process advances, militizumab is expected to enter the domestic market in the future, providing a new option for domestic patients with inflammatory bowel disease. In addition, participating in clinical trials or paying attention to special imported drug channels can also provide patients with early access to this new treatment option.

In general, militizumab is gradually establishing its core position in the field of IL-23p19 inhibitors globally. Once launched in China, it will provide a safe, efficient and convenient treatment for patients with moderate to severe inflammatory bowel disease. This innovative biologic not only improves disease symptoms, but also maintains long-term intestinal health, improves patients' quality of life, and provides continued impetus for modern treatment of inflammatory bowel disease.

Reference materials:https://omvoh.lilly.com/